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Abstract
Background:  Inactivated HVJ (hemagglutinating virus of Japan; Sendai virus) particles (HVJ
envelope vector; HVJ-E can incorporate and deliver plasmid DNA, siRNA, antibody and peptide
and anti-cancer drugs to cells both in vitro and in vivo. We attempted to eradicate tumors derived
from mouse colon cancer cells, CT26, by combining bleomycin (BLM)-incorporated HVJ-E (HVJ-E/
BLM) with cisplatin (CDDP) administration.
Methods:  CT-26 tumor mass was intradermally established in Balb/c mice. HVJ-E/BLM was
directly injected into the tumor mass with or without intraperitoneal administration of CDDP. The
anti-tumor effect was evaluated by measuring tumor size and cytotoxic T cell activity against CT26.
Re-challenge of tumor cells to treated mice was performed 10 days or 8 months after the initial
tumor inoculation.
Results:  We found that three intratumoral injections of HVJ-E/BLM along with a single
intraperitoneal administration of CDDP eradicated CT26 tumors with more than 75% efficiency.
When tumor cells were intradermally re-injected on day 10 after the initial tumor inoculation,
tumors on both sides disappeared in most of the mice that received the combination therapy of
HVJ-E/BLM and CDDP. Eight months after the initial tumor eradication, surviving mice were re-
challenged with CT26 cells. The re-challenged tumors were rejected in all of the surviving mice
treated with the combination therapy. Cytotoxic T lymphocytes specific for CT26 were generated
in these surviving mice.
Conclusion: Combination therapy consisting of HVJ-E and chemotherapy completely eradicated
the tumor, and generated anti-tumor immunity. The combination therapy could therefore be a
promising new strategy for cancer therapy.
Background
Although surgery, chemotherapy, and radiotherapy have
contributed to the successful treatment of cancer, there are
still many cases of cancer that are not eradicated by these
treatments. The treatment of advanced and metastatic
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cancers and the prevention of recurrence are the most dif-
ficult problems for cancer therapy.
Oncolytic viruses have received attention from researchers
because of their powerful killing effect on cancer cells
[1,2]. Some viruses have been discovered from viral
mutants [3] or constructed by viral genome engineering
[4,5]. The oncolytic viruses have worked very well in ani-
mal tumor models. However, they have been less success-
ful in the treatment of humans [6]. Moreover, tumor-
selective replication of the viruses is not strict enough to
prevent viral replication in non-cancerous cells [7],
although the efficiency of replication is much lower than
that in cancer cells.
To minimize the side effects of oncolytic viruses, we have
been focusing on the anti-tumor activities of inactivated
HVJ particles (HVJ-E). We recently found that HVJ-E itself
mediates a powerful anti-tumor effect by enhancing
cytokine production in dendritic cells (DCs), generating
tumor-specific cytotoxic T cells (CTLs), and inhibiting reg-
ulatory T-cell activity [8]. However, direct tumor-killing
by HVJ-E was not detected in murine tumors.
HVJ-E was originally developed as a novel drug delivery
system [9]. We tested the feasibility of HVJ-E vector for the
delivery of anticancer reagents and found that bleomycin
(BLM), an anticancer antibiotic, could be delivered to can-
cer cells by the HVJ-E vector approximately 300-fold more
effectively than by BLM alone [10]. Taken together, our
data suggest that HVJ-E enables the creation of a vector
system with the dual functions of drug delivery and
immunostimulation. However, in Mima's report [10], the
HVJ-E containing bleomycin (HVJ-E/BLM) was adminis-
tered into intraperitoneal cavity disseminated with colon
cancer cells. The anti-tumor effect of HVJ-E/BLM on solid
tumors remains to be examined.
In the present study, we demonstrated that intra-tumor
injection of HVJ-E/BLM combined with systemic adminis-
tration of cis-diamminedichloroplatinum (II) (CDDP;
cisplatin) achieved highly effective tumor eradication by
both inducing anti-tumor immunity and delivering anti-
cancer reagent to tumors.
Methods
Preparation of BLM-incorporated HVJ-E vector
HVJ-E vector was prepared as previously described [9].
Briefly, 100 µl of 10000-fold diluted HVJ seed solution
was injected into the allantoic cavity of 10-day-old embry-
onated chicken eggs. After 3 days of incubation, the allan-
toic fluid was harvested and the titer of recovered virus
(live HVJ) was measured in hemagglutination units
(HAU). An HVJ suspension (6000 HAU) was inactivated
by irradiation (99 mJ/cm2) and mixed with 60 µl of 40
mg/ml bleomycin (BLM) and 2 µl of 3% Triton X-100.
After incubating for 15 min at 4°C, the suspension was
washed with 500 µl of saline (Otsuka, Tokyo, Japan) and
centrifuged (15000 g) for 15 min at 4°C to obtain HVJ-E
vector. Then, the suspension was washed an additional
two times with 500 µl of saline to completely remove the
detergent and the unincorporated BLM. After centrifuga-
tion, the HVJ-E/BLM was suspended in 180 µl of saline.
The efficacy of BLM inclusion into the vector was quanti-
tatively measured with HPLC. The amount of BLM in
1000 HAU of HVJ-E/BLM was 0.18 µg when 5 mg/ml BLM
was used, 0.41 µg with 10 mg/ml BLM, 0.84 µg with 20
mg/ml BLM, 1.12 µg with 30 mg/ml BLM, 1.32 µg with 40
mg/ml BLM, 1.34 µg with 50 mg/ml BLM and 1.52 µg
with 100 mg/ml BLM. Thus, the amount of BLM incorpo-
rated into the HVJ-E vector increased in proportion to the
BLM concentration up to 40 mg/ml of BLM and plateaued
at BLM concentrations greater than 40 mg/ml. The 40 mg/
ml concentration of BLM was used to prepare the HVJ-E/
BLM used in these experiments.
In vitro experiments
CT-26 cells (American Type Culture Collection, Manassas,
VA, USA) were maintained in DMEM (Nakalai Tesque,
Kyoto, Japan) supplemented with 10% fetal bovine
serum, penicillin (50 units/ml) (Nakalai), and streptomy-
cin (50 µg/ml) (Nakalai) and incubated at 37°C in a 5%
CO2. HVJ-E/BLM was prepared with 40 mg/ml of BLM
diluted with saline. BLM (BLEO) was purchased from
Nippon Kayaku (Tokyo, Japan).
In vivo experiments
All animal experiments were approved by the Animal
Committee of Osaka University and conducted in a
humane fashion according to their guidelines. Male
BALB/c mice, 5–6 weeks of age, were obtained from
Charles River Japan, Inc (Yokohama, Japan). Mice were
housed for 7 days and allowed free access to food and
water. For tumor cell implantation, CT-26 cells were enzy-
matically detached from culture flasks and counted. Via-
ble cells (5 × 106) were resuspended in 100 µl of PBS and
intradermally (i.d.) injected into the right flanks of the
mice. Five days after tumor inoculation, intraperitoneal
(i.p.) administration of 200 µg of CDDP (Platosin Inj 10,
Pfizer, Tokyo) and/or intratumoral (i.t.) injections of 100
µl of HVJ-E/BLM (5000 HAU) (day 1 and/or 6 day and/or
9 day after CDDP injection) were administrated. After
injection of CDDP, tumor size was measured every 3 days,
and survival of the animals was monitored. Tumor vol-
ume was calculated using the following formula: tumor
volume (mm3) = length × (width)2/2.
Cytotoxic T lymphocyte (CTL) assay
Spleen cells were harvested 10 days after CDDP adminis-
tration. The spleen cells (5 × 106 cells/well) were co-cul-BMC Medicine 2007, 5:28 http://www.biomedcentral.com/1741-7015/5/28
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tured with mitomycin C (MMC)-treated tumor cells at a
ratio of 20:1 in 24-well plates. Each well contained 2 ml
of T-cell culture medium that consisted of RPMI1640
medium supplemented with 10% heat-inactivated FBS,
antibiotics, and 50 µM 2-mercaptoethanol. Cells were cul-
tured at 37°C in 5% CO2. These cells, which contained
CTLs, were harvested after 5 days of culture and used as
effector cells in a standard 4-h 51Cr release assay to exam-
ine the cytolytic activity of effector cells against target
tumor cells. Briefly, target tumor cells (1 × 106) were
labeled with 100 µCi of 51Cr (Amersham Bioscience,
Buckinghamshire, UK) in 200 µl of RPMI1640 supple-
mented with 10% FBS for 90 min at 37°C. The labeled tar-
get cells (1 × 104 cells/well) were incubated with the
effector cells in 96-well microtiter plates. Cells were incu-
bated in 200 µl of T-cell medium for 4 h at 37°C. Various
effector/target (E/T) ratios were used. The plates were then
centrifuged, and the radioactivity of the supernatants was
counted using a MicroBeta Trilux Scintillation Counter
(Wallac, Gaithersburg, MD, USA). The maximum release
was defined as the counts from samples incubated with
2% Triton X-100, and the spontaneous release was
defined as the counts from samples incubated with
medium alone. Cytolytic activity was calculated using the
following formula: percentage of specific 51Cr release =
(experimental release - spontaneous release) × 100/(max-
imum release-spontaneous release). Assays were per-
formed in duplicate wells. The spontaneous release of all
assays was <20% of the maximum release.
Re-challenge experiment
Fifteen days after the CDDP administration that was fol-
lowed by single or multiple injections of HVJ-E/BLM, the
BALB/c mice were re-challenged by intradermal (i.d.)
injection of 5 × 106 CT-26 cells (n = 5) or Meth A cells (n
= 5). The injection site was proximal to (but not the same
as) the initial injection site. After tumor challenge, the
tumor size was measured with calipers every 3 days. The
measurements were made in a blinded manner. Tumor
volume was then calculated.
Eight months after the tumors were eradicated in four
mice (9 months after the initial tumor inoculation), these
mice were re-challenged by i.d. injection of 5 × 106 paren-
tal cells into the back.
Results
HVJ-E/BLM combined with CDDP treatment can eradicate 
the established tumor mass
We compared anti-tumor effects of the combination of
HVJ-E/BLM and CDDP with HVJ-E/BLM alone or CDDP
alone. As shown in Figure 1, 21 days after treatment, the
tumor volume of mice treated with HVJ-E containing 1.32
µg BLM was 29.9% less than that of the non-treated con-
trol mice, whereas HVJ-E alone resulted in 15.5% suppres-
sion in tumor volume. The suppression of tumors injected
with 6.5 µg BLM alone was almost same as that with HVJ-
E alone (data not shown). With i.p. injection of CDDP
without HVJ-E/BLM, mice showed a 46.5% suppression
of tumor volume; however, CDDP alone did not eradicate
the tumors. The CDDP-mediated decrease in tumor size
was transient; eventually all of the tumors continued to
grow. By contrast, when HVJ-E/BLM was intratumorally
injected one day after CDDP administration, mice had a
68.2% suppression of tumor volume. Remarkably, in 2 of
the 10 mice treated with CDDP and HVJ-E/BLM, the
tumors were eradicated. After CDDP administration, the
body weight of mice treated with CDDP alone or CDDP
plus HVJ-E/BLM group decreased transiently, but statisti-
cally, no significant difference was seen in the body
weight between mice treated with CDDP alone and mice
treated with CDDP plus HVJ-E/BLM (Figure 1B).
CDDP and multiple injections of HVJ-E/BLM increase the 
frequency of tumor eradication
Considering that HVJ-E is a potent immune adjuvant [8],
multiple injections of HVJ-E can be more effective for
tumor suppression by eliciting anti-tumor immunity. We
compared the tumor suppression mediated by multiple
Effect of HVJ-E/BLM combined with CDDP and body weight Figure 1
Effect of HVJ-E/BLM combined with CDDP and body 
weight. (A) The effect of HVJ-E/BLM combined with CDDP 
treatment against CT-26 tumors. When tumors in the dorsa 
of BALB/c mice reached 5 mm in diameter, HVJ-E (5000 
HAU, i.t.), HVJ-E/BLM (5000 HAU, i.t.), CDDP (i.p.), or 
CDDP (i.p.) plus HVJ-E/BLM (5000 HAU, i.t.) was adminis-
tered. The tumor diameter was measured every 3 days. 
Results are expressed as the mean (n = 8 per group). Data 
are representative of each group. Two independent experi-
ments were performed. CDDP and HVJ-E/BLM treated 
tumor growth was strongly suppressed compared with saline 
treated tumors (control). *p < 0.05. By contrast, no signifi-
cant difference (NS) was seen between control and CDDP 
alone. Results were statistically analyzed using the Steel-
Dwass test. (B) The body weight of each groups. Data are 
expressed as means ± SD. No significant difference was seen 
in all groups.
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i.t. injections of HVJ-E/BLM with that mediated by a single
injection of HVJ-E/BLM. In both cases, mice received a sin-
gle i.p. CDDP treatment. Three repeated i.t. injections of
HVJ-E/BLM into the established CT-26 tumors were per-
formed on days 1, 6, and 9 after a single i.p. injection of
CDDP on day 0. After 21 days, the tumors in one of four
(25%) mice that received a single injection of HVJ-E/BLM
had been eradicated. Multiple injections of HVJ-E/BLM
increased the percentage of tumors that were eradicated to
more than 75% (three of four mice in this experiment,
four of five mice and four of four mice in two other exper-
iments) (Figure 2), indicating that multiple injections of
HVJ-E/BLM were extremely effective in eradicating
tumors.
Multiple injections of HVJ-E/BLM induce the eradication 
of not only primary tumor but also secondary tumor
We assessed the CT-26 tumor cell re-challenge experi-
ment. Ten days after CDDP treatment, CT-26 cells were
intradermally injected into the trunk at a site opposite to
the initial injection site. The initial tumor was eradicated
in 25% of mice (one of four) that received a single injec-
tion and 60% of mice (three of five) that received multiple
injections. The re-challenge tumor was not rejected in the
single-injection mice and the control mice; however, 80%
of the mice (four of five) that received multiple injections
rejected the re-challenge tumor on day 20 after the re-chal-
lenge (Figure 3). The re-challenge tumor mass in the sin-
gle-injection mice was nearly identical to the tumor mass
in the control mice; however, the tumor mass was sup-
pressed in the multiple-injection mice (Figure 3). These
data show that multiple injections of HVJ-E/BLM after
CDDP treatment are able to eradicate the initial tumor
and also reject the re-challenge tumor.
Therefore, we assessed the survival rates of mice treated
with CDDP plus HVJ-E/BLM (one or three injections)
(Figure 4). Tumors were eradicated in 80% of mice that
received CDDP and multiple injections of HVJ-E/BLM. No
recurrence of tumors was observed in those mice for 8
months. Control mice and the mice treated with a single
injection of HVJ-E/BLM and CDDP ultimately succumbed
to the CT-26 tumor. The mice able to eradicate their CT-
26 tumors survived for a prolonged time period, whereas
the control mice and the mice treated with single injection
of HVJ-E/BLM and CDDP were all dead by day 63 after
intra-dermal inoculation of CT-26 tumor cells. The eradi-
cation rates of established tumors were markedly
increased by the combined treatment of CDDP and mul-
tiple injections of HVJ-E/BLM. Consequently, the survival
times of mice receiving CDDP and multiple HVJ-E/BLM
injections were significantly prolonged.
Tumor volume and eradication rate Figure 3
Tumor volume and eradication rate. (A) Tumor volume 
of re-challenged parental CT-26 cells. Animals that were 
treated with CDDP and one (single) or three (multiple) injec-
tions of HVJ-E/BLM were intradermally re-challenged with 5 
× 106 parental CT-26 cells on day 10 after CDDP administra-
tion (arrow). The initial (upper) and re-challenged (lower) 
tumor volumes per mouse were assessed (mean value ± 
standard deviation). p < 0.05, single vs multiple injection, Stu-
dent's t test. The control mice were age-matched mice that 
were intradermally inoculated with CT-26 cells. (B) Eradica-
tion rate of initial or re-challenge tumor. On day 31 after 
CDDP administration (on day 16 after re-challenge) the 
tumors – whether visible or invisible – were examined.
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The effect of multiple injections of HVJ-E/BLM on tumor sup- pression Figure 2
The effect of multiple injections of HVJ-E/BLM on 
tumor suppression. Multiple injections of HVJ-E/BLM were 
administered. The effect of an i.p. injection of CDDP, fol-
lowed by a single injection or multiple injections of HVJ-E/
BLM on days 1, 6, and 9 was investigated. Results are 
expressed as means ± SD (n = 4 per group). p < 0.05, single 
vs multiple injection, Student's t test.
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Immune response against CT-26 tumor cells is maintained
The mice were challenged with CT-26 cells 8 months after
they had eradicated the primary CT-26 tumor As shown in
Figure 5, the age-matched control mice were uniformly
susceptible to this CT-26 challenge. However, the mice
that rejected the initial tumor were resistant to the CT-26
i.d. challenge at 8 months after the initial tumor eradica-
tion (Figure 5). The mice that eradicated the CT-26 cells
could not eradicate the Meth-A cells from a different cell
line (data not shown). These results indicate that the com-
bination of CDDP and multiple injections of HVJ-E/BLM
induced long-term anti-CT-26 immunity.
To examine anti-tumor immunity, we investigated
whether treatment with CDDP plus multiple injections of
HVJ-E/BLM induces MHC class I-restricted CT-26-specific
CTLs. CTL activity against CT-26 cells was examined in the
splenic lymphocyte samples isolated from mice treated
with CDDP plus HVJ-E/BLM. After in vitro re-stimulation
of the splenic lymphocytes with CT-26 cells, we only
found a CT-26-specific CTL response in mice that were
treated with CDDP plus multiple injections of HVJ-E/BLM
(Figure 6). Thus, the multiple i.t. injections of HVJ-E/BLM
in combination with a single i.p. CDDP administration
could not only eradicate the established CT-26 tumor but
also induced long-term immune memory against CT-26
cells in mice.
Discussion
In this study, we demonstrate that multiple i.t. injections
of HVJ-E/BLM combined with a single i.p. administration
of CDDP was the most effective treatment for eradicating
The induction of CTLs by injection of CDDP and/or HVJ-E/ BLM Figure 6
The induction of CTLs by injection of CDDP and/or 
HVJ-E/BLM. When tumors were 5 mm in diameter, CDDP 
was i.p. injected and HVJ-E/BLM was injected on days 1, 6, 
and 9 after CDDP treatment (CDDP+B/H). On day 10, mice 
were sacrificed and splenocyte cells were re-stimulated with 
CT-26 cells for 5 days, and 51Cr release was subsequently 
assayed. Results are expressed as means (n = 2 per group), 
representative of two independent experiments. E:T ratio 
indicates the effector cell to target cell ratio.
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injected with HVJ-E/BLM on day 1 or days 1, 6, and 9 after 
CDDP treatment (i.p.) on day 0. Control mice had no treat-
ment after CT-26 tumor injection. Results are representative 
of two independent experiments. Results were statistically 
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Long-term anti-tumor immunity Figure 5
Long-term anti-tumor immunity. Mice that rejected the 
initial i.d. tumor derived from CT-26 cells were re-challenged 
intradermally with 5 × 106 parental cells 8 months after the 
initial tumor eradication (9 months after the initial tumor 
inoculation). Tumor growth was observed after 30 days 
(upper: a control mouse; lower: a mouse that previously era-
diated the initial tumor). n = 2.
control
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CT26 tumors in most of the tumor-bearing mice. It
appears that this combination therapy induced tumor-
killing by chemotherapy and anti-tumor immunity
induced by multiple injections of HVJ-E. In chemother-
apy, HVJ-E/BLM significantly suppressed tumor growth,
but systemic administration of CDDP was indispensable
for effective killing of tumors.
We recently reported that HVJ-E itself induced a remarka-
ble infiltration of DCs, CD4+ T cells, and CD8+ T cells into
tumors and activated tumor-specific CTLs [8]. Moreover,
by inducing the secretion of IL-6 from DCs, HVJ-E inhib-
ited regulatory T cells, which suppress effector T cells [8].
In our current study, multiple HVJ-E/BLM injections into
initial tumors suppressed the growth of tumors subse-
quently implanted on the opposite side of the mouse, and
mice showing a complete response rejected a re-challenge
with the same tumor cells. CTLs against CT26 were highly
activated in the tumor-free mice. These results indicate
that multiple injections of HVJ-E/BLM into primary
tumors can eradicate metastatic tumors and mediate pro-
phylactic activity against initial tumors.
In our recent paper [8], HVJ-E alone eradicated CT26
tumors, while, as shown in Figure 1, HVJ-E alone was less
effective than HVJ-E/BLM. In the former case, we injected
5 × 105 cells per mouse. However, in the present study, 5
× 106 CT26 cells were intradermally injected into one
mouse. The growth rate of tumors was quite different
between both cases. In the former case, on day 20, the
tumor reached approximately 600 mm3, but in our
present study, the volume was 2700 mm3. Thus, the
tumor model was much more aggressive in our current
study than in the previous one. HVJ-E/BLM effectively
eradicated tumors even in such an aggressive tumor
model, whereas HVJ-E alone failed in tumor regression.
Therefore, HVJ-E/BLM is obviously superior to HVJ-E
alone in terms of therapeutic efficacy.
Although anti-tumor immunotherapy holds great prom-
ise, there have been many obstacles to its development
[11,12]. Although current immunotherapy can reduce,
delay, or prevent tumor recurrence, many tumors still
progress because of the development of mechanisms to
avoid recognition and elimination by the immune system
[13,14]. The mechanisms of immune system evasion
include down-regulation of antigen-processing compo-
nents and antigen-presentation machinery, weak priming
of tumor immunity, and the induction of T-cell tolerance
by immunosuppressive molecules produced from cancer
cells [15-18]. These problems are a considerable challenge
to successful cancer therapy. Therefore, to produce more
effective cancer immunotherapy, tumor volume should
be reduced as much as possible. Indeed, immunotherapy
is often combined with other therapy such as surgical
resection, radiotherapy, and chemotherapy [19,20].
Chemotherapy and radiotherapy have been frequently
used for the treatment of inoperable tumors. However,
chemotherapy and radiotherapy often weaken anti-tumor
immunity due to the suppression of bone marrow stem
cell function [21]. To increase cytotoxicity of anti-cancer
drugs with minimal damage to non-cancerous tissues,
new drug delivery systems have been considered. For this
purpose, numerous synthetic vectors such as liposomes
and micelles have been developed [22]. With these vec-
tors, anti-cancer drugs can be delivered to tumors much
more effectively than by circulatory delivery alone [23]. A
drug-delivery vector with adjuvant properties is the most
appropriate system to achieve both direct tumor killing
and anti-tumor immunity induction. Consequently, HVJ-
E seems to be an ideal vector system. Furthermore, it is
likely that the anti-tumor immunity induced by HVJ-E can
be retained even when combined with chemotherapy.
We have already reported anti-tumor effects of HVJ-E in
other murine tumor models. Renal cancers transplanted
to Balb/c mice intradermally were completely eradicated
by three times injection of HVJ-E alone [24] and ortho-
topic bladder carcinoma was suppressed by intravesical
injection of HVJ-E with doxorubicin[25]. Activation of
anti-tumor immunity was detected in both cases after
HVJ-E treatment.
In a human xenograft tumor model, T cell-mediated anti-
tumor immunity is not induced. However, the growth of
HeLa cell tumors in SCID mice were dramatically inhib-
ited by intratumoral injection of HVJ-E containing Rad51
siRNA with intraperitoneal administration of cisplatin
[26]. Thus, in a human xenograft tumor model, HVJ-E can
suppress tumors by the ability of drug delivery.
Treatment with CDDP plus multiple injections of HVJ-E/
BLM enhances therapy against primary tumors and meta-
static lesions as well as prophylactic activity against tumor
recurrence.
We have developed the technologies to produce large
amounts of HVJ and to purify HVJ-E and established a
pilot plant to produce clinical grade vectors. We will pro-
ceed to clinical trials to treat cancers using HVJ-E in a few
years.
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